Back
Prof Simon Mackay
 
Prof Simon Mackay, Professor of Medicinal Chemistry, in Strathclyde
"I've always wanted to work in drug discovery with an enthusiastic and passionate team"
 

Prostate cancer: discovering new drugs to treat the disease

£8,261 in donations so far!

 

 
0
£500,000

 Make your donation go further with Gift aid

Recent donors

View all
daveawstewart

daveawstewart donated £320.51

I have recently received treatment for testicular cance... more


139hunty

139hunty donated £19.23

This donation is instead of buying christmas cards for ... more


fredandjoan

fredandjoan donated £32.05

We want to support Murph's Mo Bros group in Australia a... more


penandnen

penandnen donated £64.10

We are supporting Murph's Mo Bros Australia and making ... more


vic239

vic239 donated £38.46

Prompted by Cancer Research UK's Christmas Appeal, I'd ... more


report a comment

Share this project

It's easy to get your friends and family involved using the form below.

 

What’s this project about?

Prostate cancer is the most common cancer in men in the UK and sadly around 10,000 die from the disease each year. So it is crucial that we find new ways to tackle the disease. Professor Simon Mackay is leading a large multi-disciplinary team of experts who are working together to discover new drugs with fewer side effects for prostate cancer.

Read more about the science.

What is the science behind the project?

Many prostate cancers are fuelled by the male hormone testosterone. Men often receive treatments that block the action of testosterone and stop cancer cells growing. But unfortunately, although for many men this can be effective, after several months or years, some prostate cancers can develop resistance to the treatment. Doctors call this hormone-refractory prostate cancer (HRPC).

HRPC is much more difficult to treat. As part of our new drug discovery initiative, Professor Mackay’s team are searching for new ways to tackle this form of cancer.

Traditional chemotherapy treatments work by killing rapidly dividing cells in the body. But this means that patients can suffer from unpleasant side effects, as healthy cells are also affected. So scientists are working hard to develop drugs that target and specifically kill cancer cells, while aiming to leave healthy cells unharmed. These so-called ‘smart drugs’, exploit subtle molecular differences in cancer cells that distinguish them from healthy cells. Scientists hope that they will provide doctors with effective new treatments that have fewer side effects.

Professor Mackay’s exciting new drug discovery programme aims to identify potential new smart drugs to treat men with HRPC. One aspect of this programme involves purifying chemicals from plants to use as a source for potential new drugs. The research team will further develop the most promising compounds for testing in future clinical trials.

Working together

In order to carry out this ambitious programme of research, Professor Mackay has pulled together a large team of doctors and scientists. These include molecular biologists, chemists, and doctors who specialise in treating men with prostate cancer. Bringing together these experts in one team combines the knowledge, skills and resources required to discover better treatments for men with hormone-refractory prostate cancer.

One of Cancer Research UK’s goals for 2020 is to develop better treatments with fewer side effects. Professor Mackay’s drug discovery programme could bring us closer to achieving this goal for men with prostate cancer.

For more information about prostate cancer you can visit our CancerHelp UK website prostate cancer pages.

Hide this content.

The difference you can make

Professor Mackay’s drug discovery programme could bring us closer to developing better treatments with fewer side effects for men with prostate cancer.

Please help us raise £500,000 to help fund one year of Professor Mackay’s five-year ground breaking research programme to beat prostate cancer.

Donate now and you can help Professor Mackay’s team discover better treatments for men with prostate cancer.